GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Cyclically Adjusted Price-to-FCF

Enzo Biochem (Enzo Biochem) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Enzo Biochem Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Enzo Biochem's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Cyclically Adjusted Price-to-FCF Chart

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enzo Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enzo Biochem's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Enzo Biochem's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Cyclically Adjusted Price-to-FCF falls into.



Enzo Biochem Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Enzo Biochem's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, Enzo Biochem's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.178/129.4194*129.4194
=-0.178

Current CPI (Jan. 2024) = 129.4194.

Enzo Biochem Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201404 0.043 100.023 0.056
201407 0.017 100.520 0.022
201410 -0.068 100.176 -0.088
201501 -0.091 98.604 -0.119
201504 -0.048 99.824 -0.062
201507 0.084 100.691 0.108
201510 0.274 100.346 0.353
201601 0.139 99.957 0.180
201604 -0.076 100.947 -0.097
201607 0.765 101.524 0.975
201610 -0.018 101.988 -0.023
201701 -0.058 102.456 -0.073
201704 0.004 103.167 0.005
201707 0.029 103.278 0.036
201710 0.045 104.070 0.056
201801 -0.050 104.578 -0.062
201804 -0.040 105.708 -0.049
201807 -0.053 106.324 -0.065
201810 -0.140 106.695 -0.170
201901 -0.321 106.200 -0.391
201904 0.467 107.818 0.561
201907 -0.078 108.250 -0.093
201910 -0.049 108.577 -0.058
202001 -0.128 108.841 -0.152
202004 -0.092 108.173 -0.110
202007 -0.136 109.318 -0.161
202010 -0.038 109.861 -0.045
202101 -0.028 110.364 -0.033
202104 0.011 112.673 0.013
202107 -0.030 115.183 -0.034
202110 -0.146 116.696 -0.162
202201 -0.038 118.619 -0.041
202204 -0.035 121.978 -0.037
202207 -0.194 125.002 -0.201
202210 -0.192 125.734 -0.198
202301 -0.145 126.223 -0.149
202304 -0.116 127.992 -0.117
202307 -0.353 128.974 -0.354
202310 -0.272 129.810 -0.271
202401 -0.178 129.419 -0.178

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enzo Biochem  (NYSE:ENZ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Enzo Biochem Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (Enzo Biochem) Business Description

Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
Executives
Steven J Pully director 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf 10 percent owner 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian officer: Chief Executive Officer 527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert officer: Interim CFO C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon officer: Chief Operating Officer 527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff director 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench officer: CHIEF FINANCIAL OFFICER ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp 10 percent owner HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri director 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv 10 percent owner 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank 10 percent owner, other: See Remarks ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203